Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607420 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of B-cell Non-Hodgkin Lymphoma (B-NHL), sponsored by Cellectis S.A..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 10
- Study locations
NCT05607420: Recruiting Phase 1 study of B-cell Non-Hodgkin Lymphoma (B-NHL), sponsored by Cellectis S.A..
NCT05607420 is a Phase 1 study of B-cell Non-Hodgkin Lymphoma (B-NHL) that is actively recruiting participants, run by Cellectis S.A.. The registered enrollment target is 80 participants, below the 215-participant average among 3 other B-cell Non-Hodgkin Lymphoma (B-NHL) trials with a reported enrollment target (63% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607420, a Phase 1 study of B-cell Non-Hodgkin Lymphoma (B-NHL), is actively recruiting participants, sponsored by Cellectis S.A..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 10
- Study locations
Study Summary
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Primary Outcome
Incidence, nature and severity of adverse events and serious adverse events in relation to UCART20x22 and/or lymphodepletion
Conditions Studied
Interventions
- BIOLOGICAL CLLS52
- BIOLOGICAL UCART20x22
Study Locations (10)
Other
- Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu - Nantes
- Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS) - Seville
Illinois
- The University of Chicago Medical Center (UCMC) - Chicago
Massachusetts
- Harvard Medical School - Massachusetts General Hospital - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick - New Brunswick
Texas
- Sarah Cannon - St. David South Austin Medical Center - Austin
Auvergne Rhone Alpe
- Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud - Pierre-Bénite
Occitanie
- Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi - Montpellier
Île-de-France Region
- Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT05607420 shows while recruiting
NCT05607420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 215-participant average among 3 other B-cell Non-Hodgkin Lymphoma (B-NHL) trials with a reported enrollment target (63% lower).
The record links to 1 condition, with B-cell Non-Hodgkin Lymphoma (B-NHL) appearing as the primary indexed condition, and to 2 interventions - of which CLLS52 is the first listed.
NCT05607420 lists 10 locations in 9 states (Other, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05607420 about?
NCT05607420 is a clinical study titled "Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma". First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum To...
What is the current status of trial NCT05607420?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2022-11-01. Estimated completion is 2027-08.
What conditions does trial NCT05607420 study?
This clinical trial studies the following conditions: B-cell Non-Hodgkin Lymphoma (B-NHL).
What interventions are being tested in trial NCT05607420?
The interventions under investigation include: CLLS52 (BIOLOGICAL), UCART20x22 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05607420?
This trial is sponsored by Cellectis S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607420 being conducted?
This trial has 10 study locations across Illinois, Massachusetts, New Jersey, Texas, Auvergne Rhone Alpe. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Non-Hodgkin Lymphoma (B-NHL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI